In the case of Amjevita, the two-price approach highlights the lack of transparency in the healthcare system as well as the incredibly confusing way in which drugs are priced in the U.S. Rebates obfuscate an already bewildering and fragmented pricing maze.
Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita
